Enochian Biosciences, Inc. (NASDAQ:ENOB) shares rose in Thursday trading. Seraph Research Institute and Enochian BioSciences published a case report of complete remission of recurrent glioblastoma with innovative therapy.
The companies announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. The important findings were published today, in the peer-reviewed American Journal of Case Reports. Enochian and Seraph also said complete remission response such as this is uncommon for this highly aggressive and deadly form of brain cancer.
In compliance with U.S. Food and Drug Administration guidance, Seraph treated the patient with natural killer (NK) and dendritic cells (DC) from a relative who had a partial genetic mismatch. The DCs were loaded with a component of cytomegalovirus that is known to be present in more than 90 percent of glioblastomas.
Enochian BioSciences acquired the intellectual property for an approach that is similar to the one used for this successful clinical outcome. The novel, proprietary strategy includes genetic modification of DCs, potentially increasing the immune response and even more effectively attacking tumors.
Enochian is dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. The company’s gene-modified cell therapy platform can be applied to multiple indications, including HIV/AIDS, Hepatitis B, and Oncology.
ENOB shares took on 58 cents, or 16.7%, to $4.08.
